Sun Pharma stock is seeing a huge drop in the morning. Shares of the
company declined by 12 percent at Rs 833 has come. Market analysts
say that Sun Pharma profit warning is issued for the current fiscal.
Pressure on the company's stock. After the news, Sun Pharma giant
brokerage houses also have slashed their target.
Why is Sun Pharma stock
decline
Sun Pharma profit warning is
issued for the current fiscal. The company says it will raise the
cost of the merger of Ranbaxy, which may have put pressure on
margins.On the margins may be pressured. Since fiscal year 2016
growth will improve. Consolidation in the coming years, while the
company will break from business.
Sun Pharma Managing Director
Dilip Sanghvi Analysts also said, "We will see the reality of
adverse news that may come in the coming days to be ready to handle
themselves Sanghvi Hoga. Akikrn process with the FDA issue 'Financial
Year after 2016 'will have gone. He indicated that exposure to loss
under the products prepared at the option of the other sites can be
adopted.
Brokerage House deductible
target
> Makwayri Sun Pharma,
target reduced from Rs 1100 to Rs 1000 has been fixed. In the
financial year 2016-17 EPS estimates by 15 per cent and 10 per cent
cut.
> Bank of America Merrill
Lynch downgraded Sun Pharma target of Rs 950 to Rs 1063 has been
fixed. EPS estimates for the financial year 2016-17 and 20 per cent
in the 30% cut.
> Barclays Ikwlvet on Sun
Pharma has set a target of Rs 922 while maintaining the rating.
> Morgan Stanley's
overweight rating on Sun Pharma reduced from Rs 1010 to Rs 1047 while
maintaining the target is fixed.
> Jefrij purchase on the
Sun Pharma has set a target of Rs 1100 while keeping opinion.
According to him, raising concerns that delays in Halol plant.
